The top 10 biopharma pipeline blowups, setbacks and snafus for H2 2019
Every 6 months, as longtime followers will know, I like to list the top 10 disasters in clinical R&D. And it seems like every new round-ups the ante a little more on just what qualifies for a top blooper of the year.
H2 2019 is certainly a standout, with a Big Pharma data scandal, a couple of blockbuster M&A busts and a whole run of Alzheimer’s setbacks to contemplate as we watch the Biogen saga play out. Not only does the Alzheimer’s field continue to crater, but we watched antibiotics come apart in the last 6 months of 2019.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
